China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its in-house developed Category 1 drug candidate, HSK31679, has obtained clinical trial approval for the treatment of non-alcoholic steatohepatitis (NASH).
HSK31679: A Selective THR-β Agonist for Lipid Metabolism
HSK31679 is a highly selective thyroid hormone β receptor (THR-β) agonist that targets key steps in lipid metabolism by binding to the thyroid hormone β receptor. This mechanism of action is designed to reduce cholesterol and liver fat, addressing the underlying issues associated with NASH. The drug’s ability to modulate lipid metabolism positions it as a potential treatment for improving liver health in patients with NASH.
Dual Development for Primary Hypercholesterolemia
In addition to its development for NASH, HSK31679 is also being developed to treat primary hypercholesterolemia. The drug has already entered into a Phase II study for this indication, demonstrating the broad potential application of HSK31679 in managing lipid-related health conditions.
The Significance of HSK31679’s Clinical Trial Approval
The clinical trial approval for HSK31679 marks a significant step forward in the development of new therapeutic options for NASH, a condition that affects a growing number of individuals worldwide. As Haisco Pharmaceutical progresses with clinical trials, the potential approval and launch of HSK31679 could provide much-needed treatment options for patients suffering from NASH and related lipid disorders.-Fineline Info & Tech
